Pharma marketing exec on how health brands are trading clinical claims for cultural currency—and what the FDA's latest warning means for the future.

Definium's CMO talks about evaluating psychedelic medicine(s) in the modern era and developing novel treatments for mental health disorders.

Dr. Amanda Randles explains how they are developing digital twins to move medicine beyond static snapshots to dynamic, personalized care.

Dr Bryony Henderson, a former frontline GP, on reframing your career, overcoming guilt, and finding purpose at scale.

Real-world data and three-year trial results show sustained remission and symptom control with Skyrizi and Rinvoq.

Bora Pharma exec, J.D. Mowery, discusses how geopolitical shifts are reshaping pharmaceutical manufacturing and supply chain strategy.

Sensei stock surges after acquiring Faeth Therapeutics and securing $200 million private placement to advance cancer pipeline.

AI-driven collaboration between the Israeli company and Queensland University of Technology targets cellular pathways to overcome treatment hurdles in non-small cell lung cancer.

London-based AI startup raises seed funding to tackle certification delays in medical devices and industrial sectors.

New AI software aims to help radiologists assess lung nodule cancer risk and improve early detection.

Immunai CEO Noam Solomon details four pivotal studies shaping the future of immunology and oncology research, as part of the ‘Grand Collaboration’.

Deepali Suri, President of ICON Biotech, discusses Asia’s clinical trial boom, funding shifts, and why neurology and cardiology are surpassing oncology.

The Sciensus team discusses how ambient AI captures patient sentiment to augment nurses, personalise care, and help keep patients healthier at home.

Vyriad's Luke Russell explores the technical and economic promise of in vivo CAR T-cell therapies.

Kum Ming Woo advises prioritizing supplier quality & availability over cost, emphasizing geographic diversification and stage-appropriate strategies.

New peer-reviewed research indicates nerve function is key to healing tissue once considered unsalvageable.

myTomorrow’s Danny den Hamer identifies two trends for 2026: hospitals adopting local AI/trusted partners, and a rise in certified AI medical devices.

Fund lead, Dr. Pini Orbach, talks about the fund targeting oncology, immunology, inflammation, rare diseases, and their aim to be an active partner from day one.

Partnership will support the supply for Becton, Dickinson and Company's self-administered therapies with a ready-to-use, scalable platform.

The gene therapy is being developed to treat a rare pediatric metabolic disease, methylmalonic acidemia (MMA).

Brainomix's e-Lung AI will provide quantitative imaging biomarkers as a co-primary endpoint in Boehringer Ingelheim's Phase III DROP-FPF study.

The US Department of Defense (DoD) grant funds engineered NK cell therapy for resistant prostate cancer.

Abbott's $21 billion Exact Sciences buyout sets stage for high-stakes MCED battle, Elena Ming talks about the major players in the sector and hurdles.

The US FDA approves Stereotaxis' robotic magnetic navigation catheter for complex cardiac arrhythmia procedures.

ICON exec discusses the increasing timeframe from site selection to full activation, including the issues contributing to the delay and measures to address them.

EA Pharma initiates a pivotal study of the novel glutamate modulator, evenamide, for treatment-resistant schizophrenia in Japan.

The Series B funding is expected to finance the expansion of Canopy’s connected safety platform across US health systems.

Endogene.bio’s research reveals how single-cell analysis predicts drug efficacy, enabling targeted treatments for endometriosis subgroups.

The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.

The US-based company’s CEO talks about how novel biomaterial tackles the hidden crisis of chronic wounds, blending ancient remedies with modern science to prevent amputations.

CNS Pharmaceuticals’ CMO explains how they are re-engineering old chemotherapies to penetrate the brain, aiming for a breakthrough in treating aggressive glioblastoma.

The company’s exec talks about how new analyses bolster the case for Copiktra in tough-to-treat lymphomas, informing a pivotal Phase III trial strategy.

Swiss biotech raises Series A financing to advance PARG inhibitor FORX-428, with initial clinical data expected in 2026.

CTMC’s Amy Hay details a partnership model to share knowledge and expand cell therapy access worldwide, starting with Brazil.

The at-home treatment is designed to manage acute symptomatic episodes outside of emergency healthcare settings.

Dr. Margaret Kalmeta, CEO of Rapid Nexus, discusses the first device cleared to treat the tissue around chronic wounds and the company’s pipeline.

Agendia’s VP of clinical development notes that new FLEX study data show genomic signatures predict chemotherapy benefit, improving personalized treatment for early breast cancer.

A cable-free, credit-card sized ECG device for at-home heart monitoring receives regulatory approval, paving the way for a 2026 launch.

Interim Phase II data suggest its vaccine candidate may slow progression, a potential first in Parkinson's treatment.

Lithuanian bioinformatics firm launches into pharmaceutical services via a strategic CRO collaboration aimed at accelerating multi-omics analysis.

Sanofi’s head of rare diseases, Jeff Schaffnit, outlines the company's dual approach: redefining hemophilia care and pioneering immune modulation for rare blood disorders.

Vyome's VT-1953 gel significantly reduced odor and pain in malignant fungating wounds, prompting plans for a pivotal Phase III study.

New preclinical data show Gene Writing tech exceeding key efficacy benchmarks for sickle cell disease and in vivo CAR-T generation.

Swedish company reveals how LIB-01, an erectile dysfunction therapy, works via the melanocortin system, offering sustained effects and possible hope for non-responders.

Dr. Victoria Miles discusses how RECELL, which creates an autologous skin cell suspension, is reshaping burn care, access, and outcomes.

Concurrently with the collaboration deal for ILYX-002 for autoimmune-associated dry eye disease, Iolyx announced a $15 million Series B financing.

Dr. Christian Tidona, founder and CEO of BioMed X, on why women's health is critically underfunded and how a new initiative aims to change that.

The company’s oral drug deucrictibant significantly sped up symptom relief in the Phase III trial, positioning it for 2026 regulatory filings.

The study indicated that Brainomix 360 Stroke led to a 100% increase in endovascular thrombectomy rates and sped up patient transfers across 107 UK hospitals.

UK researcher Prof. Vaiyapuri discusses how Covid vaccine technology could soon neutralize deadly snake venom, preventing death and disability for millions.